# A Study of LY3435151 in Participants With Solid Tumors

> **NCT04099277** · PHASE1 · TERMINATED · sponsor: **Eli Lilly and Company** · enrollment: 2 (actual)

## Conditions studied

- Solid Tumor
- Triple-negative Breast Cancer
- Gastric Adenocarcinoma
- Head and Neck Squamous Cell Carcinoma
- Cervical Carcinoma
- High Grade Serous Ovarian Carcinoma
- Hepatocellular Carcinoma
- Undifferentiated Pleomorphic Sarcoma
- Leiomyosarcoma

## Interventions

- **DRUG:** LY3435151
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT04099277
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-10-28
- **Primary completion:** 2020-03-05
- **Final completion:** 2020-03-05
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Study terminated due to strategic business decision by Eli Lilly and Company.
- **Last updated:** 2021-08-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04099277

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04099277, "A Study of LY3435151 in Participants With Solid Tumors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04099277. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*